Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0

In this older grp of pts w/ chronic LBP, significant overlaps of deg & inflamm features on spinal imaging of DC, DISH & axSpA pts were seen Also, +comorbids: HTN in DC; DM in DISH; smoking in axSpA THM? DC & DISH are also axSpA mimics #ACR23 ABST1862 @Rheumnow @rheumarhyme https://t.co/uNIwRchF1g

Will postpartum BME ⏩axSpA-like structural lesions? Study by Varkas et al show there was no significant dev't of axSpA-like lesions on MRI in postpartum women 5 yrs after delivery. Postpartum BME likely sec to transient mech stress-induced SI BME #ACR23 ABST1892 @RheumNow https://t.co/KJ3DngmkbI

Always refreshing to hear from another specialist's point of view Cardiologist @Bweber04 on CVD and rheumatologic diseases Increased risk of death, MI and HF exacerbation in our pt population Increased all cause mortality @RheumNow #ACR23 https://t.co/yOkPOmxU4N

Later today at #ACR23 at 4pm See Ab#2545 on IV secukinumab for AxSpA Read about it now on @RheumNow: https://t.co/s9IinpVxgR

Amazing & thoughtful poster re:protocol violates in TICOSPA trial 51.2% of pts violated T2T protocol at least once... but did not impact primary outcome Good baseline for future "strategy" style pragmatic trials @RheumNow #ACR23 #ACRBest Abstr2201 https://t.co/FhctgFNdNP

CV Events in AS by Rx A#L11 @RheumNow #ACR23 43K pts from Korean data Rates of incident MI or CV: 18.7 per 10,000 py in non-bDMARD pt 8.9 in TNF 12.9 in IL-17 TNFi reduced risk of CVD HR 0.7, not signif for IL-17 Supports idea of TNFi giving a cardioprotective effect? #ACRBest https://t.co/SvVVDSU23z

Real-World Issues in AxSpA: Treatment Intensification, Pregnancy Dr. Rabab Nezam El-Din and colleagues explored patient- and disease-related determinants that were associated with treatment intensification among axSpA patients w/ high disease activity. https://t.co/vZ66hsErBI https://t.co/pN8JZAEcqv

• Real-World Issues in AxSpA: Treatment Intensification, Pregnancy | RheumNow

Be a SpA (and PsA) Sleuth! My article is your call to arms for better understanding and discovery of IBD in our inflammatory back pain patients. Consider fecal calprotectin AND robust ROS as your magnifying glass! #ACR23 @rheumnow https://t.co/OnQDEWgIWM

From patient to research/clinical rheumatologist and SpA advocate. Check out my #ACR23 interview with Dr. Hillary Norton. @DrHillaryNorton @RheumNow https://t.co/SeZeqb8wid